Ypsomed
Martin B. has a range of work experience in various roles and companies. Martin started their career at Disetronic Medical Systems in 2004 as an Entwicklungsingenieur. Martin then moved to nanoTRONIC GmbH in 2007, where they worked as a HW Entwicklungsingenieur and later as an Entwicklungsingenieur HW/Marketing until 2015. In 2016, they joined nanoTRONIC as a Gruppenleiter HW and was also briefly appointed as Stellvertretender Geschäftsführer. Most recently, Martin has been working at Ypsomed AG since 2017, initially as a Technical Leader and currently as a Business Intelligence Team Lead.
Martin B. completed an eMBA degree at PHW Bern from 2010 to 2012. Prior to that, they attended HTA-BE Hochschule für Technik und Architektur Bern from 2000 to 2004, where they earned a degree in Ingenieur FH with a focus on Elektro- und Kommunikationstechik.
Ypsomed
4 followers
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.